Evotec SE
Evotec SE (EVOTF) Revenue
Annual & quarterly revenue history · segment & region breakdown
EVOTF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsEvotec SE trailing twelve-month (TTM) revenue is $0.75B, a decrease of 1.12% year-over-year from $0.79B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.79B | -$0.01B | -1.12% |
| 2024-12-31 | $0.80B | +$0.02B | +1.99% |
| 2023-12-31 | $0.78B | +$0.03B | +3.99% |
| 2022-12-31 | $0.75B | +$0.13B | +21.59% |
| 2021-12-31 | $0.62B | +$0.12B | +23.38% |
| 2020-12-31 | $0.50B | +$0.05B | +12.20% |
| 2019-12-31 | $0.45B | +$0.07B | +18.92% |
| 2018-12-31 | $0.38B | +$0.12B | +45.71% |
| 2017-12-31 | $0.26B | +$0.09B | +56.61% |
| 2016-12-31 | $0.16B | +$0.04B | +28.85% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare EVOTF revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Evotec SE receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Evotec SE reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Evotec SE's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EVOTF revenue · 4 questionsEVOTF's trailing twelve-month (TTM) revenue is $0.75B. That is a decrease of 1.12% year-over-year from $0.79B in FY2025.
▸ Source: FMP · Evotec SE SEC filings · GAAP · Evotec SE SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026